Clinicopathologic Features and Response to Pembrolizumab Neoadjuvant Therapy in Triple Negative Breast Cancer (TNBC): A Single Institution Experience

被引：0
|
作者：
Carames, Gian [1 ]
Ning, Bohan [2 ]
Khoury, Katia [1 ]
Wei, Shi [3 ]
Xu, Jia [1 ]
Guo, Hua [2 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] UAB Hosp, Birmingham, AL USA
[3] Univ Kansas, Sch Med, Kansas City, KS USA
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
108
引用
收藏
页码：S128 / S129
页数：2
相关论文
共 50 条
  • [1] Clinicopathologic Features and Response to Neoadjuvant Chemotherapy in Metaplastic Breast Carcinoma: A Single Institution Experience
    Hashem, Sherin
    Nguyen, Luan
    Hasteh, Farnaz
    Fadare, Oluwole
    Zare, Somaye
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 127 - 128
  • [2] Clinicopathologic Features and Response to Neoadjuvant Chemotherapy in Metaplastic Breast Carcinoma: A Single Institution Experience
    Hashem, Sherin
    Nguyen, Luan
    Hasteh, Farnaz
    Fadare, Oluwole
    Zare, Somaye
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 127 - 128
  • [3] Immune phenotype and response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC).
    Yam, Clinton
    Alatrash, Gheath
    Yen, Er-Yen
    Garber, Haven
    Philips, Anne V.
    Huo, Lei
    Yang, Fei
    Bassett, Roland L.
    Sun, Xiangjie
    Cuentas, Edwin Roger Parra
    Symmans, William Fraser
    Seth, Sahil
    White, Jason B.
    Rauch, Gaiane M.
    Damodaran, Senthil
    Litton, Jennifer Keating
    Wargo, Jennifer Ann
    Hortobagyi, Gabriel N.
    Moulder, Stacy L.
    Mittendor, Elizabeth A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] RESPONSE TO NEOADJUVANT THERAPY AND DISEASE FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (TNBC): SINGLE CENTER EXPERIENCE
    Pascual, T.
    Ciruelos, E.
    Manso, L.
    Ghanem, I.
    Manneh, R. A.
    Mendiola, C.
    Lora, D.
    Cortes-Funes, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 134 - 134
  • [5] A SINGLE INSTITUTION EXPERIENCE WITH TRIPLE NEGATIVE BREAST CANCER
    Rezazadeh, A.
    Kloecker, G.
    Kruse, B. B.
    Jain, D.
    ANNALS OF ONCOLOGY, 2009, 20 : 49 - 49
  • [6] TOLERABILITY OF BEVACIZUMAB IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC) PATIENTS: A SINGLE INSTITUTION EXPERIENCE
    Stamatovic, Ljiljana
    Vasovic, Suzana
    Milovic-Kovacevic, Marijana
    Karaferic, Andjela
    Lukic, Vesna
    Pupovac, Simonida
    BREAST, 2013, 22 : S50 - S51
  • [7] Current usage of pembrolizumab in triple negative breast cancer (TNBC)
    O'Rourke, Harriet
    Hart, Christopher
    De Boer, Richard H.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (05) : 253 - 261
  • [8] Androgen Receptor Positive Triple Negative Breast Cancer (TNBC): Clinicopathologic and Prognostic Features
    Astvatsaturyan, Kristine
    Yue, Yong
    Bose, Shikha
    LABORATORY INVESTIGATION, 2017, 97 : 30A - 30A
  • [9] Androgen Receptor Positive Triple Negative Breast Cancer (TNBC): Clinicopathologic and Prognostic Features
    Astvatsaturyan, Kristine
    Yue, Yong
    Bose, Shikha
    MODERN PATHOLOGY, 2017, 30 : 30A - 30A
  • [10] The neoIRX trial:locoregional cytokine therapy to promote immunologic priming and enhanced response to neoadjuvant pembrolizumab plus chemotherapy in triple negative breast cancer (TNBC)
    Sanchez, Katherine
    Conlin, Alison
    Peddi, Parvin
    Stanton, Sasha
    Ruzich, Janet
    Perlewitz, Kelly
    Wu, Yaping
    Moxon, Nicole
    Mellinger, Staci
    Sun, Zhaoyu
    Redmond, William
    Page, David B.
    CANCER RESEARCH, 2022, 82 (04)
12345